<< Back to News

System Formulary Update
Cardiac Ultrasound Contrast

Situation:

The cardiac ultrasound contrast product standardization was approved by the System Pharmacy & Therapeutics Committee in November 2023.

Background:

The following medications were reviewed: Perflutren lipid microspheres 0.65 mg/mL intravenous suspension (Definity); Perflutren lipid microspheres 1.1 mg/mL intravenous suspension (Definity); Perflutren protein-type A microspheres 0.22 mg/mL intravenous suspension (Optison); Sulfur hexafluoride microspheres 25 mg intravenous suspension (Lumason)

Assessment/Recommendations:

System P&T voted to include the following product from the UNC Health Medication Formulary:

• Perflutren lipid microspheres 1.1 mg/mL intravenous suspension (Definity)
• Perflutren protein-type A microspheres 0.22 mg/mL intravenous suspension (Optison)

System P&T voted to exclude the following products on the UNC Health Care System Drug Formulary:

• Sulfur hexafluoride microspheres 25 mg intravenous suspension (Lumason)
• Perflutren lipid microspheres 0.65 mg/mL intravenous suspension (Definity RT)

Note: Stock of this formulary product may vary at individual entities 

Formulary/Epic Changes will Go-Live on Tuesday, January 23, 2024